Teva Pharmaceutical Industries (TEVA) Net Income towards Common Stockholders (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Net Income towards Common Stockholders for 18 consecutive years, with $370.0 million the latest figure, recorded in Q1 2026.

• Quarterly Net Income towards Common Stockholders rose 68.18% year-over-year to $370.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 billion (up 217.3% YoY) and the FY2025 annual result came in at $1.4 billion, up 171.58% from the prior year.
• Net Income towards Common Stockholders declined to $370.0 million in Q1 2026 per TEVA's latest filing, from $470.0 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for TEVA reached as high as $519.0 million in Q1 2024 and fell as low as -$1.8 billion in Q4 2023.
• A 5-year average of -$273.7 million and a median of -$253.0 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders sank 1286.59% — and 2024, when it soared 305.14%.
• Year by year, Net Income towards Common Stockholders stood at -$1.3 billion in 2022, then slumped by 34.63% to -$1.8 billion in 2023, then surged by 84.69% to -$275.0 million in 2024, then jumped by 270.91% to $470.0 million in 2025, then fell by 21.28% to $370.0 million in 2026.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered $370.0 million, $470.0 million, and $432.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.